Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Questionable efficacy of the rVSV-ZEBOV Ebola vaccine – Authors’ reply

We thank Wolfram Metzger and Sarai Vivas-Martínez for expressing their concern about potential sources of bias in the final analysis of our ring vaccination trial of an rVSV-vectored vaccine for Ebola virus disease (rVSV-ZEBOV).1 In that trial, the point estimate of vaccine efficacy was 100%, with no confirmed cases of Ebola virus disease detected in vaccinated people 10 days or more after vaccination in the entire trial. We were careful to ascertain that the risk of exposure to Ebola virus and case ascertainment were low and statistically the same in the rings (clusters) that received immediate and delayed vaccination.